Kymera Therapeutics Announces Pricing of $250 Million Public Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
Stifel Defending Kymera Therapeutics (KYMR): 'We see any weakness from today's news as a buying opportunity'
June 27, 2025 12:19 PM EDTStifel analyst Alex Thompson reiterated a Buy rating and $68.00 price target on Kymera Therapeutics (NASDAQ: KYMR).
The analyst comments "We are reiterating our Buy Rating on KYMR following a slate of updates including the decision by partner Sanofi to discontinue development of... More
